Abstrait

Evolution of uncontrolled severe asthma under Omalizumab and specialized care unit treatment.

Alberto Levy-Nahon, Lorena Pinel-Jimenez*, Jesus Ramirez-Rodrigo, Lucia Prieto, Victoria Hidalgo-Sanjuan M and Pedro Valdivielso

Severe uncontrolled asthma is a disabling and life-threatening disorder. This article evaluates the effectiveness of combining a specialized care clinic treatment with the prescription of Omalizumab (OML) when treating these patients. We analyzed 45 patients with severe uncontrolled asthma followed for 12 months, of which 30 had elevated levels of IgE and received omalizumab dose adjusted for weight and IgE levels. The overall effectiveness was measured through parameters such as emergency room visits (ER), the evolution of forced expiratory volume in one second (FEV1), the need for high-dose corticosteroids; Fractional exhaled nitric oxide (FENO) and a quality of life survey. At three, six and twelve months, all patients improved significantly in all measured parameters (p<0.05), except FENO, as a result of their treatment in the specialist office. The changes were even more favorable for patients who received OML in addition to the visits to the specialized care clinic, showing a significant interaction between drug use and clinical visit factors. Our results confirm that the benefits obtained in randomized clinical trials with OML and the specialist care of patients with severe asthma result in a significant clinical benefit in the context of everyday clinical practice.